Ciamexon (Ciamexone) is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.Ciamexon can be used to study endocrine ophthalmopathies and diabetes mellitus, with slight improvement in ophthalmic disease following short-term administration.

4-(2,6,6-Trimethyl-1-cyclohexenyl)-3-buten-2-one is a natural product for research related to life sciences.

R715 是一种选择性缓激肽 B1 受体 (bradykinin B1 receptor) 拮抗剂。R715 显著减弱 Streptozotocin 诱导的糖尿病小鼠的痛觉过敏作用。